{"id":"W4389899921","doi":"10.1097/hep.0000000000000726","title":"Adjuvant and neoadjuvant therapies for hepatocellular carcinoma","year":2023,"lang":"en","type":"article","venue":"Hepatology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre; Toronto General Hospital","funders":"","keywords":"Medicine; Oncology; Sorafenib; Adjuvant; Internal medicine; Clinical trial; Atezolizumab; Bevacizumab; Clinical endpoint; Adjuvant therapy; Hepatocellular carcinoma; Cancer; Immunotherapy; Nivolumab; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002191028,0.0002398616,0.00056133,0.0002359841,0.0001504827,0.00001680904,0.00006917084,0.0001932045,0.000089164],"category_scores_gemma":[0.00005731269,0.0001977402,0.0001752566,0.0002639257,0.0001385928,0.00004728943,0.00005876685,0.0001130737,0.0001489253],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003461413,"about_ca_system_score_gemma":0.00009329469,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000789673,"about_ca_topic_score_gemma":0.00001265166,"domain_scores_codex":[0.9985711,0.0000596147,0.0002789615,0.0004404673,0.0001358036,0.0005140347],"domain_scores_gemma":[0.9991642,0.0001884164,0.00005968474,0.0003088109,0.00008576204,0.0001930768],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001804359,0.00005505593,0.9788251,0.0001371446,0.0001164266,0.000619969,0.0004575983,2.279031e-8,0.002697773,0.001279928,0.002937066,0.01269348],"study_design_scores_gemma":[0.01170542,0.003525709,0.4527734,0.0001078398,0.001096204,0.001624886,0.0008495649,0.2101185,0.02963259,0.005445279,0.2820856,0.001035088],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9887092,0.004589413,0.0001503661,0.004539906,0.0002185774,0.001026933,0.00003169727,0.000283022,0.000450949],"genre_scores_gemma":[0.9963471,0.000549026,0.0007456373,0.0005349689,0.0001277148,0.0003759268,0.0002183808,0.00005244841,0.001048843],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5260517,"threshold_uncertainty_score":0.806361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07839865103530189,"score_gpt":0.276469474019007,"score_spread":0.1980708229837051,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}